Junqiang Lv
Impact in
- Rehabilitation top 10%
- Exercise and Physiological Responses
-
- Escherichia coli research studies
Papers in
-
- Histone Deacetylase Inhibitors Research 3
- Signaling Pathways in Disease 2
- Oncology 9
- Peptidase Inhibition and Analysis 5
- Co-authors
- Zhi Yao (14 shared papers)Quan Wang (10 shared papers)Rong Lu (8 shared papers)Zhi‐Song Zhang (6 shared papers)Lijuan Chen (2 shared papers)Huali Zhang (2 shared papers)Xiaolei Li (2 shared papers)Rui Ma (2 shared papers)
- Journals
- Anti-Cancer Drugs (3 papers)Frontiers in Immunology (2 papers)Cell Reports (2 papers)Peptides (2 papers)Inflammation Research (1 paper)
- Partner nations
- ChinaUnited StatesSaudi Arabia
In The Last Decade
Junqiang Lv
25 papers receiving 468 citations
Peers
Comparison fields: 5 of 87
- Rehabilitation 56
- Endocrinology 30
- Biological Psychiatry 10
- Complementary and alternative medicine 32
- Molecular Biology 258
Countries citing papers authored by Junqiang Lv
This map shows the geographic impact of Junqiang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junqiang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junqiang Lv more than expected).
Fields of papers citing papers by Junqiang Lv
This network shows the impact of papers produced by Junqiang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junqiang Lv. The network helps show where Junqiang Lv may publish in the future.
Co-authors
The 25 scholars most cited alongside Junqiang Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 120 | |
| 2 | 2023 | 50 | |
| 3 | 2017 | 39 | |
| 4 | 2019 | 35 | |
| 5 | 2020 | 33 | |
| 6 | 2022 | 30 | |
| 7 | 2020 | 26 | |
| 8 | 2022 | 19 | |
| 9 | 2018 | 18 | |
| 10 | 2010 | 16 | |
| 11 | 2021 | 15 | |
| 12 | 2018 | 15 | |
| 13 | 2013 | 13 | |
| 14 | 2024 | 11 | |
| 15 | 2022 | 8 | |
| 16 | Herbal formula of Bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle. | 2021 | 7 |
| 17 | 2024 | 4 | |
| 18 | 2011 | 4 | |
| 19 | 2008 | 3 | |
| 20 | 2007 | 3 |
About Junqiang Lv
Junqiang Lv is a scholar working on Molecular Biology, Oncology, Immunology, Epidemiology and Pathology and Forensic Medicine, having authored 28 papers that have together received 478 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (5 papers), Cancer Mechanisms and Therapy (4 papers), Escherichia coli research studies (3 papers), Urinary Tract Infections Management (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Multiple Myeloma Research and Treatments (3 papers) and Signaling Pathways in Disease (2 papers). The work is most often cited by research in Rehabilitation (56 citations), Endocrinology (30 citations), Biological Psychiatry (10 citations), Complementary and alternative medicine (32 citations) and Molecular Biology (258 citations). Junqiang Lv has collaborated with scholars based in China, United States and Saudi Arabia. Frequent co-authors include Zhi Yao, Quan Wang, Rong Lu, Zhi‐Song Zhang, Lijuan Chen, Huali Zhang, Xiaolei Li, Rui Ma, Lı Wang and Yanjiao Zhou. Their work appears in journals such as Anti-Cancer Drugs, Frontiers in Immunology, Cell Reports, Peptides and Inflammation Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.